Orally Available Selective Melanocortin-4 Receptor Antagonists Stimulate Food Intake and Reduce Cancer-Induced Cachexia in Mice by Weyermann, Philipp et al.
Orally Available Selective Melanocortin-4 Receptor
Antagonists Stimulate Food Intake and Reduce Cancer-
Induced Cachexia in Mice
Philipp Weyermann*, Robert Dallmann, Josef Magyar, Corinne Anklin, Martina Hufschmid, Judith
Dubach-Powell, Isabelle Courdier-Fruh, Marco Hennebo ¨hle, Sonja Nordhoff, Cesare Mondadori
Santhera Pharmaceuticals (Switzerland) Ltd., Liestal, Switzerland
Abstract
Background: Cachexia is among the most debilitating and life-threatening aspects of cancer. It represents a metabolic
syndrome affecting essential functional circuits involved in the regulation of homeostasis, and includes anorexia, fat and
muscle tissue wasting. The anorexigenic peptide a-MSH is believed to be crucially involved in the normal and pathologic
regulation of food intake. It was speculated that blockade of its central physiological target, the melanocortin (MC)-4
receptor, might provide a promising anti-cachexia treatment strategy. This idea is supported by the fact that in animal
studies, agouti-related protein (AgRP), the endogenous inverse agonist at the MC-4 receptor, was found to affect two
hallmark features of cachexia, i.e. to increase food intake and to reduce energy expenditure.
Methodology/Principal Findings: SNT207707 and SNT209858 are two recently discovered, non peptidic, chemically
unrelated, orally active MC-4 receptor antagonists penetrating the blood brain barrier. Both compounds were found to
distinctly increase food intake in healthy mice. Moreover, in mice subcutaneously implanted with C26 adenocarcinoma cells,
repeated oral administration (starting the day after tumor implantation) of each of the two compounds almost completely
prevented tumor induced weight loss, and diminished loss of lean body mass and fat mass.
Conclusions/Significance: In contrast to the previously reported peptidic and small molecule MC-4 antagonists, the
compounds described here work by the oral administration route. Orally active compounds might offer a considerable
advantage for the treatment of cachexia patients.
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Introduction
Cachexia is among the most debilitating and life-threatening
aspects of cancer. It is associated with anorexia, fat and muscle
tissue wasting, and a progressively decreasing quality of life [1].
The presence of cachexia is a predictor of poor survival. Up to
80% of patients with cancer develop cachexia before death, and
in over 20% of all cases cachexia is responsible for the death of
the patient [2,3]. At the moment of diagnosis, about 80% of
patients with gastrointestinal cancers and 60% of patients with
lung cancer have substantial weight loss. In general, patients with
solid tumors (with the exception of breast cancer) have a higher
frequency of cachexia [4]. Cachexia is a predictor of poor
outcome not only for cancer patients but also in various other
chronic diseases [5–8].
Even though the exact nature of the underlying mechanisms
remains largely unknown, it is evident that cachexia represents a
metabolic syndrome caused by a complex interaction between the
tumor and the host. Cachexia is characterized by major metabolic
abnormalities and maladaptations: Food and therefore energy
intake is reduced, resting energy expenditure is often increased
and catabolism is accelerated [3]. The emerging view is that
cachexia represents the clinical consequence of a chronic, systemic
inflammatory response and many of the physiological, metabolic,
and behavioral changes of cachexia have been found to be tightly
regulated by cytokines. For example, cytokines have been found to
be involved in depletion of skeletal muscle [9], signaling the
synthesis of acute-phase proteins [e.g. 10], regulation of energy
expenditure [e.g. 11], and decreased food intake [e.g. 12].
One mechanism by which the cytokines (and other appetite
regulating molecules such as leptin) can induce anorexia is via the
regulation of pro-opiomelanocortin (POMC) expression [13].
POMC is a precursor molecule for important endogenous peptides
such as adrenocorticotropin (ACTH), a-, and b-melanocyte
stimulating hormone (a-MSH and b-MSH), c-Lipotropin and b-
Endorphin which are produced via cleavage by tissue specific
enzymes. POMC neurons are mainly located in the arcuate
nucleus of the hypothalamus. POMC neurons are considered to
have major regulatory functions in food intake and energy
expenditure. It is assumed that these effects are predominantly
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inhibiting effects [14].
Alpha-MSH, the endogenous ligand at the MC-4 receptor,
and other agonists at the MC-4 receptor have been found to
inhibit food intake, increase energy expenditure and reduce body
weight. Inversely, disruption of melanocortin signaling with
agouti related peptide (AgRP) or small molecule MC-4 receptor
antagonist treatment or deletion of the receptor led to increased
food intake and reduced energy expenditure [15–18]. Accord-
ingly, in the context of creating a treatment option for cachexia
patients it was speculated that interruption of this signaling
pathway could eventually reduce the progression of cachexia
[19,20].
SNT207707 and SNT207858 are the results of a major effort to
find selective, potent and orally active MC-4 receptor antagonists.
SNT207707 binds to the MC-4 receptor with an affinity of 8 nM
and shows a more than 200-fold selectivity vs. MC-3 and MC-5.
SNT207858 is a 22 nM MC-4 antagonist with a 170-fold
selectivity vs. MC-3 and a 40-fold selectivity versus MC-5
[21,22]. In order to assess the potential usefulness of these
compounds for the treatment of cachexia we evaluated their acute
effects on feeding during the light phase in healthy mice.
Moreover, we investigated the effects of repeated treatments on




SNT207707 and SNT207858 were synthesized in the
Medicinal Chemistry Department at Santhera Pharmaceuticals
(Switzerland) Ltd. All animals were held under standard
laboratory conditions (2161uC, 40–60% humidity) with 12 hrs
of light per day (05:00 to 17:00 h) and free access to food (2018S
Teklad Global, Harlan, CH) and tap water. All compounds were
freshly dissolved and administered by oral gavage at the
indicated doses in a volume of 10 ml/kg of 10% Hydroxypro-
pyl-b-cyclodextrin (Acros Organics, Geel, BE) in 100 mM saline
solution unless otherwise noted. Syngenic C26 colon adenocar-
cinoma cells (CLS Cell Line Service, Eppenheim, DE) were
cultured in serum free medium (Quantum 263; PAA Laborato-
ries, Linz, A) before implantation in animals. All animal
experiments were approved by the governmental authorities
(permission numbers BL246, BL356).
Light Phase Food Intake
Six weeks old female NMRI mice (RCC Ltd.; Fu ¨llinsdorf, CH)
were randomly assigned to the various experimental groups and
the vehicle controls. They were housed in groups of 3 mice per
cage. After at least one week of acclimatization in the experimental
room, each animal’s weight was determined and compound or
vehicle was administered at appropriate concentrations 5 hrs after
lights on. Then, food consumption of each cage group was
recorded by weighing of the food hopper over a period of 4 hrs.
Food intake was then determined as the difference in food hopper
weight at the beginning and end of the 4 hrs following
administration of the compound or the vehicle. Since the amount
of food taken over 4 hrs by single animals was close to the limit of
detection, we decided to rely on mean food amounts taken per
cage (i.e., per 3 mice), whereby each treatment group consisted of
n=6 cages. The measured values from each cage were normalized
to 100 g body weight (BW). Previous experiments indicated an
excellent correlation between food intake and reduction of food
weight.
C26 adenocarcinoma-induced cachexia model
Six week old male BALB/c mice (Harlan, The Netherlands)
were used. The animals were single housed, and after a one week
adaption period randomly assigned to the experimental or control
groups. For the tumor implantation the mice were anaesthetized
with 200 ml of ketamine/xylazine. Approximately 1610
6 C26 cells
suspended in phosphate buffered saline were then implanted
unilaterally in the flank of the mice by subcutaneous injection. The
non-tumor controls underwent the same procedure but received
PBS injection only (n=9 per group). Starting on the first day after
tumor implantation, compounds or vehicle were administered
orally in 5 ml/kg 1–2 hrs before the onset of the dark phase. Food
intake and body weight were recorded daily. Lean and fat mass of
each animal were determined by MRI relaxometry (EchoMRI-
500, Echo Medical Systems, Houston, TX, USA) prior to tumor
inoculation (day 0) and at the end of the experiment after removal
of the tumor (typically day 15).
Brain and plasma concentrations in vivo
Twelve weeks old male CD-1 (Hilltop Lab Animals, PA, USA)
mice were dosed by gavage with either SNT207707 or
SNT207858 at 60 mg/kg (n=9 per compound). At 1, 3, and
6 hrs post-dose, 3 mice from each compound group were
euthanized with CO2. Blood was collected by cardiac puncture,
plasma was isolated immediately and then kept on dry ice until
analysis. Brains were removed, rinsed with saline solution and
stored at 280uC until analysis. Levels of the compound were
determined by HPLC followed by mass spectrometry (MS/MS).
Areas under the curve (AUC) of plasma and brain levels were
computed from measured levels at 1, 3 and 6 hrs post-dose. Brain/
plasma ratios were then calculated based on the AUCs. To assess
the integrity of the blood-brain-barrier all animals were co-dosed
with 10 mg/kg Atenolol. Brain levels of Atenolol close or below
limit of detection indicated that the blood-brain-barrier was intact.
Statistics
Differences between groups were compared with (repeated)
analysis of variance (ANOVA) with Dunnett’s post hoc test where
applicable. Kaplan-Meier curves for occurrence of cachexia were
plotted with GraphPad Prism and statistically compared using the
Mantel-Cox test. All test were carried out 2-tailed with a=0.05.
All results are given as means6SEM.
Results
Light Phase Food Intake
A single subcutaneous injection of 20 mg/kg of either SNT207707
or SNT207858 distinctly increased food intake of the mice
(ANOVA p,0.001). The increase was statistically highly signifi-
cant for both compounds (p,0.01). The amount of food taken
during the four hours observation period was roughly 3-fold the
amount taken by the vehicle treated controls. Figure 1 depicts the
results graphically.
In line with the results via the subcutaneous administration
route, a single oral treatment by gavage with either SNT207707 or
SNT207858 dose-dependently increased the food intake
(ANOVA: SNT207707 p,0.01 and SNT207858 p,0.05). Single
dose comparisons revealed statistically significant increases in food
intake at 60 and 120 mg/kg for SNT207858 (p,0.01), and
120 mg/kg for SNT207707 (p,0.01). The amount of food taken
during the four hour post-treatment observation period was
roughly up to four times the amount taken by the vehicle control
group. Figure 2 is a graphical representation of the data produced.
Oral Treatment of Cachexia
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Once daily oral administration of both compounds
SNT207858 and SNT207707 starting the day after tumor
implantation significantly reduced the tumor induced weight
loss. The outcomes of the two experiments were quite
comparable: In both experiments, the tumor was palpable
around day 4 after inoculation. Similarly, in both experiments
the vehicle-treated tumor controls stopped gaining weight
around day 11 and began to show weight loss on day 13. In
both experimental series, the compounds almost completely
prevented weight loss, and the average body weight of the tumor
bearing compound treated groups was significantly higher than
that of the Vehicle+Tumor group. Figure 3 (left panel) depicts
the results graphically.
Although both compounds did greatly ameliorate symptoms of
cachexia, tumor growth in both compound groups was not altered
compared to Vehicle+Tumor group. Tumor weights in mice
treated with SNT207707 (1.0360.07 g) and SNT207858
(1.1160.09 g) were not different from those in the corresponding
control groups (1.1760.06 g and 1.1960.05 g, respectively). It has
to be noted that even though all inoculated animals developed a
tumor, not all tumor bearing mice became cachectic, i.e. lost more
than 5% of body weight in the course of the experiment.
According to this definition, cachexia was not observed in 2 of 9
and 3 of 9 animals of the Vehicle+Tumor control groups whereas
8 out of 9 in the SNT207707 and 6 out of 9 mice in the
SNT207858 treated group, respectively, did not show cachexia.
Kaplan-Meier analysis of the onset of cachexia revealed a
statistical difference between the SNT207707+Tumor (p,0.05)
and SNT207858+Tumor (p,0.01) groups each compared to
respective Vehicle+Tumor controls (Figure 4).
Both compounds were found to have distinct effects on body
composition. The non tumor vehicle controls showed increases in
fat mass and lean body mass whereas the vehicle treated tumor
animals showed distinct losses of both, fat mass and lean body
mass. Both compounds partially counteracted the cancer induced
changes, i.e. no loss but even a slight gain of fat and lean body
mass was observed. Figure 3 (middle and right panels) depicts the
results graphically.
Brain and plasma concentration in vivo
After oral application, CD-1 mice showed significant levels of
both compounds in plasma and brain (Table 1). The calculated
maximal concentrations in brain are 580 nM for SNT207707 and
110 nM for SNT207858.
Discussion
Our results show a significant enhancing effect of SNT207707
and SNT207858 on food intake over a 4 hrs observation period
after oral administration to mice. These robust orexigenic effects
confirm published findings showing that endogenous peptidic or
small molecule MC-4 receptor antagonists enhance food intake in
healthy animals [23–25]. The significance of the compound’s
enhancing effects on food intake is further supported by the fact
that in our experiments the drug-induced feeding happened
during the inactive light phase, where, under normal (non-stressed)
Figure 1. The effects of s.c. injection of Vehicle (open bar),
20 mg/kg SNT207707 (light grey bar) and 20 mg/kg
SNT207858 (dark grey bar) on light phase food intake in
healthy mice. Animals were held in groups of three. Food intake per
cage (n=6 cages/group) was recorded over a period of 4 hrs starting
after injection of compound. Each bar represents mean6SEM. Statistical
difference vs. Vehicle ** p,0.01.
doi:10.1371/journal.pone.0004774.g001
Figure 2. The effects of p.o. administration of (A) SNT207707
and (B) SNT207858 on light phase food intake in healthy mice.
Animals were held in groups of three. Food intake per cage (n=6
cages/dose) was recorded over a period of 4 hrs starting after
administration of compound. Each bar represents mean6SEM. Statis-
tical difference vs. Vehicle ** p,0.01.
doi:10.1371/journal.pone.0004774.g002
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24 hrs free access to food and water, i.e. they were not fasted.
Accordingly, the drug effects might be interpreted in terms of an
acute appetite-enhancing effect.
The results of the tumor induced cachexia experiments are
equally clear. SNT207858 and SNT207707 showed distinct anti-
cachectic effects at the dose used, i.e. both compounds almost
completely blocked the tumor induced loss of body weight, and
also had positive effects on body composition. Both, loss of lean
body mass and loss of fat mass was reduced. These anti-cachectic
effects were not due to any anti-tumor effects since determination
of the tumor growth and weight did not indicate any effect of the
compounds on the tumor. Even though all of the tumor implanted
mice did develop a tumor, and all tumors developed from a single
batch of tumor cells, there were single animals in the Vehicle+
Tumor group showing no cachexia. The reason for the lack of
cachexia is not known, but it has to be assumed that there might
have been animals not showing cachexia in the drug treated
groups as well. Nevertheless, the number of non-cachectic mice in
the Vehicle+Tumor group is significantly smaller than in the
treatment groups for both compounds (Figure 4), further
supporting a beneficial effect of the treatment. In the absence of
any useful marker to differentiate between spontaneous and drug
related absence of cachexia and in order not to bias the outcome of
the experiment all animals were included in the statistical
evaluation when comparing means for body weight or body
composition.
The observed effects of SNT207858 and SNT207707 in the
C26 cancer cachexia model are in line with previous findings by us
and other groups reporting effects of MC4-R antagonism in
animals with cancer induced anorexia. For example, MC-4
receptor blockade through the central administration of AgRP
Figure 3. The effects of (A) SNT207707 and (B) SNT207858 in C26 tumor bearing mice. Left panels: Mean body weight development of
Vehicle control (open squares), Vehicle+Tumor control (closed squares), and 30 mg/kg (A) SNT207707 and (B) SNT207858 (grey triangles) group (n=9
each). Middle and right panels: Difference in lean body mass and fat mass between day of tumor inoculation (day 0) and end of experiment (day 15).
Each value represents mean6SEM. Statistical difference vs. Vehicle+Tumor * p,0.05, *** p,0.001.
doi:10.1371/journal.pone.0004774.g003
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models of cancer-induced anorexia [20,27]. Earlier results
indicated that subcutaneous administration of the small molecule
MC-4R antagonist ML00253764 was efficacious in reducing
cachexia in animals implanted with either a colorectal tumor [28]
or Lewis lung carcinoma [23]. Consistent with these findings,
intra-peritoneal administration of NBI-12i, another MC-4R
antagonist, ameliorated cachexia in mice with implanted Lewis
lung carcinoma and uremia. This small molecule antagonist did
not only reduce tumor induced anorexia but also increased lean
body mass [24]. Finally, there is a recent summarizing report on a
whole series of compounds from Neurocrine Biosciences described
to have positive effects after intra-peritoneal administration in
cancer cachexia models [29].
In the light of the a priori hypothesis an important question
concerns the involvement of central neural circuits in the observed
appetite enhancing effects, or in other words: are the brain levels
achieved with the compounds high enough to be causally involved
in the effects? SNT207707 has an IC50 of 8 nM (binding) and
5 nM (function) on the MC-4 receptor [21]. The approximate
brain concentration in the mouse was calculated to be 580 nM
(Table 1). Accordingly, from the concentration point of view
nothing speaks against a central effect. The same holds true for
SNT207858, i.e. the maximal brain concentration is about
110 nM [22], and thus, considering the IC50s of 22 nM (binding)
and 11 nM (function), above the concentration required for
central effects (Table 1).
Facing the clear-cut effects on food intake the next question is
how far these effects per se can account for the observed anti
cachexia effects. Considering any potential interpretation of our
effects in terms of an appetite enhancing effect immediately leads
to a comparison of the active dose range in the light phase food
intake and in the cancer cachexia model. Accordingly, a significant
beneficial effect in the cancer induced cachexia experiment was
detected at 30 mg/kg p.o. (Figure 3). This effect includes
reduction of body weight loss and the positive effects on lean
body mass and fat mass. At the very same dose, in the light phase
food intake experiment, only a slight trend (if anything) towards
increased food intake could be detected (Figure 2). In support of an
appetite based interpretation many aspects contributing to a
possible dose mismatch can be brought up. First, the light phase
food intake experiments have been done with our standard
laboratory strain (NMRI) whereas, due to the need for a syngenic
tumor and mouse line, BALB/c mice have been used for the
cancer cachexia experiments. Moreover, the regulation of food
consumption is based on an extremely complicated, highly cross-
linked network involving the brain, autonomous nervous system,
gastro-intestinal tract, and adipose tissues involving a variety of
neurotransmitters, hormones and peptides [30–32]. Cachexia is
the result of a profound functional disturbance of these networks;
presumably by pro-inflammatory cytokines (see above). Accord-
ingly, the drug effects are superimposed onto a fundamentally
different background activity and therefore even more profound
Figure 4. The effects of C26 tumor on development of cachexia (defined as loss of more than 5% of body weight (BW) after
inoculation of tumor cells) in mice. (A) Left panel: Kaplan-Meyer plot for Vehicle control (dashed black line), Vehicle+Tumor control (black line),
and SNT207707 30 mg/kg (grey line) group (n=9 each). (B) Right panel: Kaplan-Meyer plot for Vehicle control (dashed black line), Vehicle+Tumor
control (black line), and SNT207858 30 mg/kg (grey line) group (n=9 each). Note: Statistical comparison between Vehicle+Tumor and treatment
groups was significant.
doi:10.1371/journal.pone.0004774.g004
Table 1. Peak plasma and brain levels and 0-6-hr plasma and
brain AUC of MC4-R antagonists SNT207707 and SNT207858
in CD-1 mice after oral application (n=3 per group).
Compound SNT207707 SNT207858
Dose [mg/kg] 60 60
Plasma peak [nM] 1960 1520
Plasma AUC [nM?h] 6373 4405
Brain peak [nM] 580 110
Brain AUC [nM?h] 2307 437
Brain/plasma ratio 0.36 0.10
Note: Brain/plasma ratio is calculated from area under the curve (AUC).
doi:10.1371/journal.pone.0004774.t001
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could have been expected.
An important aspect, speaking against an interpretation solely in
terms of an appetite enhancement is the fact that measurements of
food intake in our cancer cachexia experiments provided non
conclusive results, i.e. food consumption was extremely variable
between days of the experiment and no clear effect towards
increased food intake could be identified (data not shown).
Moreover, there is no doubt that physiological changes in
cachexia are not just involving a lack of appetite. The cachectic
patient is distinctly different with regards to metabolic adaptations.
In healthy subjects, caloric deprivation induces physiological
adaptations to conserve energy and to protect tissue. In contrast,
cancer patients show maladaptive responses resulting in inappro-
priate high energy expenditure despite low caloric intake [3].
Accordingly, therapeutic approaches aiming at both, increasing
food intake and reducing energy expenditure are expected to be
therapeutically superior to approaches aiming solely at food
intake. This particular aspect might make the MC-4 receptor
antagonist approach therapeutically most promising since the
effects of an interaction with the melanocortin signaling pathway
are expected to have consequences broader than just a modulation
of appetite. As previously mentioned, a-MSH, the endogenous
agonistic ligand at this receptor was found to have a dual action,
i.e. to reduce food intake [14] and also to increase energy
expenditure [33]. In turn, agouti related protein, the endogenous
inverse agonist to this receptor was observed to block the MC-4
receptor and, inversely to the action of a-MSH, increase food
intake and reduce energy expenditure [34]. Accordingly, via the
MC-4 receptor, two key aspects of cachexia can possibly be treated
and the anti-cachectic effects of our compounds in the C26 cancer
model might be based on such combination effects. Thus, in future
experiments, effects on energy expenditure have to be shown
experimentally, e.g., by indirect calorimetry.
Even though our results are completely in line with the
literature there is one major difference: In contrast to the above
mentioned experiments with peptidic and small molecule MC-4
antagonists, the compounds described here work by the oral
administration route. In the light of patient care, orally active
compounds might offer a considerable advantage. Moreover, it
has to be noted that SNT207707 and SNT207858 represent two
different, chemically unrelated compound classes, MC-4 receptor
blockade being the only common denominator.
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